On the filings, Intellia (NTLA) is the stronger stock right now — higher on our blended fundamentals-plus-verdict read, and we currently rate it HOLD.
Cash-burning CRISPR pioneer with two Phase 3 readouts and a 2027 launch — a binary bet, not a value buy, but underpinned by a clean balance sheet.
Clinical-stage base editor burning $345M/yr in operating cash with $295M cash — dilution is the base case, not a tail risk.
| Metric | NTLA | BEAM |
|---|---|---|
| Fundamentals score | 55 | 58 |
| Revenue growth (YoY) | +16.9% | +120.0% |
| Net income growth (YoY) | +20.5% | +78.8% |
| Net margin | -609.9% | -57.2% |
| Return on equity | -61.5% | -6.5% |
| ROIC (est.) | -51.9% | -24.5% |
| Liabilities / Equity | 0.25 | 0.20 |
| Piotroski F-score | 2 / 9 | 3 / 9 |
Bold green = the stronger figure. All rows derive from SEC XBRL filings — no market-price data on this page.
AI-generated analysis, produced by our proprietary engine from SEC filing data.
Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jun 30, 2026, 12:20 AM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.
AI-generated analysis, produced by our proprietary engine from SEC filing data.
Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jun 25, 2026, 9:27 AM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.